164 related articles for article (PubMed ID: 24595201)
1. Prevention of arterial stiffening by using low-dose atorvastatin in diabetes is associated with decreased malondialdehyde.
Wang CH; Chang RW; Ko YH; Tsai PR; Wang SS; Chen YS; Ko WJ; Chang CY; Young TH; Chang KC
PLoS One; 2014; 9(3):e90471. PubMed ID: 24595201
[TBL] [Abstract][Full Text] [Related]
2. Prevention of arterial stiffening by pyridoxamine in diabetes is associated with inhibition of the pathogenic glycation on aortic collagen.
Chang KC; Liang JT; Tsai PS; Wu MS; Hsu KL
Br J Pharmacol; 2009 Aug; 157(8):1419-26. PubMed ID: 19681870
[TBL] [Abstract][Full Text] [Related]
3. Effects of a new advanced glycation inhibitor, LR-90, on mitigating arterial stiffening and improving arterial elasticity and compliance in a diabetic rat model: aortic impedance analysis.
Satheesan S; Figarola JL; Dabbs T; Rahbar S; Ermel R
Br J Pharmacol; 2014 Jun; 171(12):3103-14. PubMed ID: 24611770
[TBL] [Abstract][Full Text] [Related]
4. Effects of low-dose atorvastatin on arterial stiffness and central aortic pressure augmentation in patients with hypertension and hypercholesterolemia.
Kanaki AI; Sarafidis PA; Georgianos PI; Kanavos K; Tziolas IM; Zebekakis PE; Lasaridis AN
Am J Hypertens; 2013 May; 26(5):608-16. PubMed ID: 23449607
[TBL] [Abstract][Full Text] [Related]
5. Carnosine decreased oxidation and glycation products in serum and liver of high-fat diet and low-dose streptozotocin-induced diabetic rats.
Aydın AF; Bingül İ; Küçükgergin C; Doğan-Ekici I; Doğru Abbasoğlu S; Uysal M
Int J Exp Pathol; 2017 Oct; 98(5):278-288. PubMed ID: 29205589
[TBL] [Abstract][Full Text] [Related]
6. Aminoguanidine prevents arterial stiffening in a new rat model of type 2 diabetes.
Chang KC; Tseng CD; Wu MS; Liang JT; Tsai MS; Cho YL; Tseng YZ
Eur J Clin Invest; 2006 Aug; 36(8):528-35. PubMed ID: 16893374
[TBL] [Abstract][Full Text] [Related]
7. Low-dose treatment with atorvastatin leads to anti-oxidative and anti-inflammatory effects in diabetes mellitus.
Riad A; Du J; Stiehl S; Westermann D; Mohr Z; Sobirey M; Doehner W; Adams V; Pauschinger M; Schultheiss HP; Tschöpe C
Eur J Pharmacol; 2007 Aug; 569(3):204-11. PubMed ID: 17669395
[TBL] [Abstract][Full Text] [Related]
8. Combined atorvastatin and coenzyme Q10 improve the left ventricular function in isoproterenol-induced heart failure in rat.
Garjani A; Andalib S; Biabani S; Soraya H; Doustar Y; Garjani A; Maleki-Dizaji N
Eur J Pharmacol; 2011 Sep; 666(1-3):135-41. PubMed ID: 21570962
[TBL] [Abstract][Full Text] [Related]
9. Aminoguanidine prevents arterial stiffening and cardiac hypertrophy in streptozotocin-induced diabetes in rats.
Chang KC; Hsu KL; Tseng CD; Lin YD; Cho YL; Tseng YZ
Br J Pharmacol; 2006 Apr; 147(8):944-50. PubMed ID: 16491102
[TBL] [Abstract][Full Text] [Related]
10. Atorvastatin reduces the plasma lipids and oxidative stress but did not reverse the inhibition of prostacyclin generation by aortas in streptozotocin diabetic rats.
Mahfouz MM; Kummerow FA
Prostaglandins Other Lipid Mediat; 2005 May; 76(1-4):59-73. PubMed ID: 15967162
[TBL] [Abstract][Full Text] [Related]
11. Effect of atorvastatin on the angiogenic responsiveness of coronary endothelial cells in normal and streptozotocin (STZ) induced diabetic rats.
Chaudagar KK; Mehta AA
Can J Physiol Pharmacol; 2014 Apr; 92(4):338-49. PubMed ID: 24708217
[TBL] [Abstract][Full Text] [Related]
12. Anti-inflammatory effects of atorvastatin improve left ventricular function in experimental diabetic cardiomyopathy.
Van Linthout S; Riad A; Dhayat N; Spillmann F; Du J; Dhayat S; Westermann D; Hilfiker-Kleiner D; Noutsias M; Laufs U; Schultheiss HP; Tschöpe C
Diabetologia; 2007 Sep; 50(9):1977-1986. PubMed ID: 17589825
[TBL] [Abstract][Full Text] [Related]
13. Advanced glycation end products accelerate rat vascular calcification through RAGE/oxidative stress.
Wei Q; Ren X; Jiang Y; Jin H; Liu N; Li J
BMC Cardiovasc Disord; 2013 Mar; 13():13. PubMed ID: 23497312
[TBL] [Abstract][Full Text] [Related]
14. Atorvastatin ameliorates sildenafil-induced penile erections in experimental diabetes by inhibiting diabetes-induced RhoA/Rho-kinase signaling hyperactivation.
Morelli A; Chavalmane AK; Filippi S; Fibbi B; Silvestrini E; Sarchielli E; Zhang XH; Vignozzi L; Vannelli GB; Forti G; Maggi M
J Sex Med; 2009 Jan; 6(1):91-106. PubMed ID: 19170840
[TBL] [Abstract][Full Text] [Related]
15. Atorvastatin ameliorates arsenic-induced hypertension and enhancement of vascular redox signaling in rats.
Sarath TS; Waghe P; Gupta P; Choudhury S; Kannan K; Pillai AH; Harikumar SK; Mishra SK; Sarkar SN
Toxicol Appl Pharmacol; 2014 Nov; 280(3):443-54. PubMed ID: 25218292
[TBL] [Abstract][Full Text] [Related]
16. Effects of olmesartan on arterial stiffness in rats with chronic renal failure.
Chuang YC; Wu MS; Su YK; Fang KM
Cardiovasc Diabetol; 2012 Jun; 11():66. PubMed ID: 22694778
[TBL] [Abstract][Full Text] [Related]
17. Renoprotective effect of atorvastatin on STZ-diabetic rats through attenuating kidney-associated dysmetabolism.
Zhou S; Zhao P; Li Y; Deng T; Tian L; Li H
Eur J Pharmacol; 2014 Oct; 740():9-14. PubMed ID: 25008071
[TBL] [Abstract][Full Text] [Related]
18. The effects of triple vs. dual and monotherapy with rosiglitazone, glimepiride, and atorvastatin on lipid profile and glycemic control in type 2 diabetes mellitus rats.
Ahmed D; Sharma M; Pillai KK
Fundam Clin Pharmacol; 2012 Oct; 26(5):621-31. PubMed ID: 21692847
[TBL] [Abstract][Full Text] [Related]
19. Arterial stiffening and cardiac hypertrophy in a new rat model of type 2 diabetes.
Chang KC; Tseng CD; Chou TF; Cho YL; Chi TC; Su MJ; Tseng YZ
Eur J Clin Invest; 2006 Jan; 36(1):1-7. PubMed ID: 16403003
[TBL] [Abstract][Full Text] [Related]
20. Atorvastatin prevents type 2 diabetes mellitus--an experimental study.
Madhu SV; Aslam M; Galav V; Bhattacharya SK; Jafri AA
Eur J Pharmacol; 2014 Apr; 728():135-40. PubMed ID: 24530420
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
